Sulfonylureas were the first oral medications for Type 2 diabetes. They arrived in the 1950s — a decade before anyone had heard of metformin in the US — and for 30 years they were essentially the only game in town. They work fast, they work hard, they cost almost nothing, and they have been prescribed to hundreds of millions of people. They are also responsible for more hypoglycemia hospitalizations than any other class of diabetes medication. That tradeoff — potent glucose-lowering at the cost of unpredictable lows and weight gain — defines why sulfonylureas are increasingly being replaced by newer drug classes in T2D management despite their low price.
Sulfonylureas bind to ATP-sensitive potassium channels (KATP channels) on pancreatic beta cells. These channels normally open when intracellular ATP falls — signaling low glucose — and close when glucose rises, triggering insulin secretion. Sulfonylureas close these channels regardless of glucose level. The channel closure depolarizes the beta cell membrane, calcium flows in, and insulin granules are released.
The consequence of this mechanism is the central clinical problem: sulfonylureas stimulate insulin secretion whether blood glucose is high or not. Unlike metformin, GLP-1s, SGLT2 inhibitors, or DPP-4 inhibitors — all of which have glucose-dependent or glucose-lowering-focused mechanisms — sulfonylureas push insulin out on a timer, not in response to actual glucose need. If you take a sulfonylurea and skip a meal, miss a snack, or exercise more than usual, you will push your glucose below safe levels. Hypoglycemia is not a rare side effect with sulfonylureas. It is an inherent pharmacological consequence of the mechanism.
A second concern: by chronically overstimulating beta cells, sulfonylureas may accelerate beta-cell exhaustion over time. T2D is already a disease of progressive beta-cell failure. The question — still debated — is whether pushing already-stressed beta cells to produce more insulin faster speeds that decline. Observational data and some mechanistic evidence suggest it does. The counterargument is that good glucose control protects beta cells from glucotoxicity. The net effect on long-term beta-cell function remains one of the unresolved tensions in T2D pharmacology.
The newest and most widely used third-generation sulfonylurea. Glimepiride is once-daily dosing (1–8mg), has a lower hypoglycemia risk profile than glyburide, and produces less weight gain than older agents. It binds the SUR1 subunit of the KATP channel with higher selectivity — meaning less effect on cardiac KATP channels than older sulfonylureas, which is relevant because cardiac KATP channels play a role in ischemic preconditioning (the heart’s protective response to brief ischemic episodes). Glimepiride also has some insulin-sensitizing properties via GLUT4 translocation, independent of its insulin secretagogue action. Generic; under $5/month. The preferred sulfonylurea in most current guidelines when a sulfonylurea is warranted.
Available in immediate-release (twice daily) and extended-release (once daily, Glucotrol XL) formulations. Glipizide has a shorter half-life than glyburide, which generally means a lower risk of prolonged hypoglycemia. Renally cleared, like all sulfonylureas, but its shorter duration of action makes it somewhat safer in elderly patients and those with mild renal impairment than glyburide. Standard doses: 5–40mg/day IR, 5–20mg/day ER. Glipizide ER has better tolerability than IR due to slower absorption reducing peak concentration. Generic; extremely inexpensive. Along with glimepiride, this is one of the two sulfonylureas most commonly continued in current practice.
Once the most prescribed sulfonylurea in the US. Glyburide has a longer half-life and produces active metabolites that are themselves hypoglycemic — meaning it continues lowering blood glucose for hours after its apparent peak. In elderly patients or those with declining renal function (which slows clearance of both the drug and its active metabolites), glyburide can cause severe, prolonged hypoglycemia that lands patients in the emergency room. The American Geriatrics Society Beers Criteria has explicitly listed glyburide as a drug to avoid in elderly patients since 2003. The FDA updated glyburide’s labeling multiple times to emphasize hypoglycemia risk in renal impairment. Glyburide is falling out of favor for both elderly and high-risk populations; glimepiride and glipizide are preferred. Still available generically and still frequently prescribed — often out of habit more than clinical rationale.
The first sulfonylurea. Short-acting (half-life ~4–5 hours), required multiple daily doses, caused significantly less hypoglycemia than later agents by virtue of its brief action. The University Group Diabetes Program (UGDP) trial in 1970 raised concerns about cardiovascular mortality with tolbutamide — a finding that was hotly contested and never definitively confirmed but contributed to a decades-long cloud over the entire sulfonylurea class. Tolbutamide is no longer marketed in the US.
The longest-acting sulfonylurea ever marketed: a half-life of 24–48 hours and renal excretion of unchanged drug made it the most hypoglycemia-dangerous agent in the class. Chlorpropamide caused a distinctive side effect — facial flushing with alcohol — that was actually used as a clinical marker to identify patients who metabolized the drug differently. It also caused hyponatremia (low sodium) via SIADH-like stimulation of antidiuretic hormone. Withdrawn from the US market; still available in some countries. A historical artifact that defined the risks the class is still managing today.
| Drug | Approved | Half-life | Hypo Risk | Weight Gain | Notes |
|---|---|---|---|---|---|
| Glimepiride (Amaryl) | 1995 | 5–9 hr | Low–moderate | Moderate | Preferred agent; some insulin sensitization |
| Glipizide (Glucotrol) | 1984 | 2–5 hr | Low–moderate | Moderate | Short half-life; ER form preferred |
| Glyburide (DiaBeta) | 1984 | 10–16 hr | High | Moderate–high | Avoid in elderly / renal impairment |
| Tolbutamide (Orinase) | 1957 | 4–5 hr | Low | Moderate | First SFU; no longer marketed in US |
| Chlorpropamide (Diabinese) | 1958 | 24–48 hr | Very high | High | Withdrawn; hyponatremia, alcohol flush |
Sulfonylureas reduce HbA1c by 1.0–2.0% as monotherapy — among the highest reductions of any oral diabetes drug class. They work quickly: meaningful glucose reduction is often visible within days to weeks of initiation. This speed and potency is why they remained so widely used for so long.
The problem is durability. Unlike metformin, which maintains its glucose-lowering effect stably over years, sulfonylurea efficacy tends to decline over time — a phenomenon called secondary failure. As beta-cell function declines with T2D progression (and possibly accelerated by the drug itself), the beta cells become less responsive to sulfonylurea stimulation. Approximately 5–10% of patients per year experience secondary failure requiring additional therapy. By 6 years of treatment, a substantial minority have lost meaningful response.
Hypoglycemia — blood glucose below 70 mg/dL — is not an edge case with sulfonylureas. It is a predictable pharmacological consequence that requires active management. In real-world T2D practice, sulfonylureas account for the majority of severe hypoglycemia episodes requiring emergency intervention or hospitalization.
Severe hypoglycemia (glucose below 54 mg/dL, requiring external assistance) carries acute risks: cardiac arrhythmia, seizure, loss of consciousness, falls, and in the elderly, hip fracture. The ACCORD trial — which aimed for very tight HbA1c control — was stopped early in 2008 when intensive glycemic control (which relied heavily on sulfonylureas and insulin) was associated with higher cardiovascular mortality than standard control. Hypoglycemia was the leading explanatory hypothesis. The ACCORD findings reinforced the principle that aggressive glucose-lowering via hypoglycemia-prone drugs carries its own cardiovascular risk.
Patients on sulfonylureas must be counseled to: never skip meals after taking their dose; carry fast-acting glucose (glucose tablets, juice) at all times; be especially careful with exercise; and know that alcohol impairs the counterregulatory response to hypoglycemia, making alcohol use on sulfonylureas significantly more dangerous than in the general population.
The UGDP trial (1970) raised concerns that tolbutamide might increase cardiovascular mortality. The finding was not replicated and was methodologically criticized, but it created a regulatory concern that haunted the entire class for decades. Subsequent sulfonylureas were required to carry a label warning about potential cardiovascular risks — a warning that persisted on labels long after the supporting evidence had been discredited.
Current evidence: second- and third-generation sulfonylureas (glipizide, glyburide, glimepiride) are considered cardiovascular neutral — they do not significantly increase or decrease major cardiovascular events. They lack the cardiovascular benefit of GLP-1 agonists, SGLT2 inhibitors, and to some extent metformin. But the old fear of active cardiovascular harm from modern sulfonylureas is not supported by the current data. The concern today is about hypoglycemia-mediated cardiovascular events and the opportunity cost of using a cardiovascular-neutral drug when cardiovascular-protective alternatives exist.
UGDP cardiovascular warning (1970, all sulfonylureas). Tolbutamide data generated a class-wide label warning about potential increased risk of cardiovascular mortality. This warning remained on labels for decades despite the original study’s flaws and lack of replication. FDA updated labeling language multiple times but retained a cautionary note through the 1990s.
Glyburide — renal impairment and elderly warnings (ongoing). FDA updated glyburide labeling to specifically warn against use in patients with significant renal impairment (eGFR below 60). The American Geriatrics Society Beers Criteria (2003 and updated every 3 years since) lists glyburide as a potentially inappropriate medication for patients 65 and older due to prolonged hypoglycemia risk from active metabolite accumulation.
ACCORD trial findings (2008). Although not a regulatory action, the early stoppage of the ACCORD trial due to excess cardiovascular mortality in the intensive glycemic control arm (which included high sulfonylurea use) changed prescribing culture significantly, reinforcing caution about aggressive sulfonylurea dosing, especially in high-cardiovascular-risk patients.
Sulfonylureas are not going away. In lower-income countries and among uninsured or underinsured patients in the US, they remain essential: glimepiride costs $4–6/month. GLP-1 agonists cost $800–1,200/month without insurance. When access to newer drugs is blocked by cost, a well-managed sulfonylurea regimen — with patient education on hypoglycemia prevention — is far better than uncontrolled hyperglycemia.
In patients with good insurance coverage, endocrinologists are increasingly skipping sulfonylureas entirely after metformin, moving directly to SGLT2 inhibitors or GLP-1 agonists based on their cardiovascular and renal benefit profiles. If a sulfonylurea is chosen, glimepiride is the preferred option on grounds of lower hypoglycemia risk, once-daily dosing, and some evidence of beta-cell-sparing relative to glyburide. Glyburide should be avoided in elderly patients and those with renal impairment. The conversation about whether any sulfonylurea is worth prescribing in a patient who has access to better alternatives is ongoing — and increasingly answered in the negative by guideline bodies.
Please understand that I’m not a doctor, and everything on this site reflects my own research and personal experience managing Type 2 diabetes. It is provided for informational and educational purposes only — not as medical advice, diagnosis, or treatment.
Before starting any supplement, changing your diet, or adjusting your medications, consult your physician or a qualified healthcare provider. Individual results vary. Never delay or disregard professional medical advice because of something you read here.
Product photos and brand names appear for illustrative purposes only. Denyabetic does not endorse, sponsor, or have any commercial relationship with any brand shown unless explicitly stated.
These statements have not been evaluated by the Food and Drug Administration. No product or protocol discussed on this site is intended to diagnose, treat, cure, or prevent any disease.